New Delhi:Russia's experimental mRNA-based cancer vaccine Enteromix has demonstrated 100% efficacy and safety in clinical trials, raising hopes for a breakthrough in the global fight against cancer. Developed using similar technology as COVID-19 vaccines, Enteromix works by training the immune system to recognize and eliminate cancer cells without serious side effects. The announcement was made by the Federal Medical and Biological Agency (FMBA) of Russia, with its head Veronika Skvortsova confirming that the vaccine had successfully completed preclinical studies and was now ready for clinical use. 100% efficacy in trials “The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced. FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating its safety and high effectiveness. The vaccine showed significant results in shrinking tumors and slowing their growth, and has also been found safe for repeated use. The vaccine will be customized for each patient, tailored to their individual RNA, Skvortsova said. She added that the first form of the vaccine will be used to treat colorectal cancer, while another version is in development for glioblastoma — a brain cancer — and specific types of melanoma, a skin cancer," Sputnik posted on X. Unlike chemotherapy and radiation, patients reportedly tolerated the vaccine well, with no serious side effects recorded during the study. How Enteromix works Enteromix was developed by Russia’s Ministry of Health’s National Medical Research Radiology Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Sciences. The vaccine uses cutting-edge mRNA technology, similar to COVID-19 vaccines, but is personalized for each patient. It trains the immune system to detect and destroy cancer cells. According to MedPath, Enteromix also makes use of four harmless viruses to attack tumors while boosting immune response. Earlier, Russia had launched clinical trials of Enteromix with 48 volunteers, announced during the St. Petersburg International Economic Forum (SPIEF 2025), held from June 18–21. Strong results in preclinical studies According to Tass, Skvortsova revealed the results at the Eastern Economic Forum (EEF): “The research spanned several years, with the last three dedicated to mandatory preclinical studies. The vaccine is now ready for use; we are awaiting official approval.” Also Read:Indian-origin scientist develops groundbreaking mrna vaccine against pancreatic cancer She further highlighted that repeated administration remained safe and effective. Tumor growth slowed by 60–80%, survival rates improved, and significant reductions in tumor size were observed, reports theEconomic Times. First target: Colorectal cancer The vaccine’s initial application will focus on colorectal cancer, a leading cause of cancer-related deaths worldwide. Research is also underway for glioblastoma (an aggressive brain tumor) and melanoma, including ocular melanoma. A milestone in cancer treatment? TOIreports that the announcement was made at the 10th Eastern Economic Forum in Vladivostok (3–6 September 2025), attended by over 8,400 delegates from 75 countries. Enteromix reportedly stole the spotlight, signaling Russia’s ambitions in medical innovation. If regulatory approval is granted by the Russian Ministry of Health, Enteromix could become the world’s first personalized mRNA cancer vaccine available for public use.